Skip to main content

Table 3 Perioperative outcomes reported in studies on preoperative chemotherapy with and without bevacizumab for CLM

From: Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases

Reference Group Duration of surgery (min) Estimated blood loss (ml) Morbidity (%) Severe morbidity (%) Wound compl. (%) Liver failure (%) Bile leakage (%) Thromboembolic events (%) Hospital stay (d) Mortality (%)
Aussilhou BEV-    50    15 5    5
BEV+    55    18 9    0
Constantinidou BEV-   650 (100–2200) 54 13 12 13   0 10 (4–32) 2
BEV+   540 (50–2000) 48 12 14 10   5 10 (4–57) 0
D’Angelica BEV- - 500 (200–5000) 38 9 6     7 (n.r.) 0
BEV+ 235 (85–500) 300 (0–1500) 41 6 19      0
Kesmodel BEV- 134 (69–408) 200 (50–1750) 43   25 7 2    2
BEV+ 139 (67–675) 250 (50–1950) 49   28 1 4    1
Lubezky BEV-    47 9 2 5 9 4   0
BEV+    35 11 2 1 8 5   2
Mahfud BEV- 270 (237–302) 658 (407–908) 40 18 9 20   9 13 (8–18) 4
BEV+ 248 (224–270) 523 (399–646) 56 31 11 7   7 15 (11–20) 0
Millet BEV- 300 (175–645) 500 (50–1700) 34 10   12    8 (5–21) 0
BEV+ 300 (156–540) 500 (150–1100) 56 12   22    9 (6–22) 0
Pessaux BEV- 277 (±55) 548 (±233) 19   0 0 0   13.7 (±4.2) 0
BEV+ 321 (±160) 983 (±1476) 29   14 0 0   12.7 (±6.3) 0
Reddy BEV-   600 (350–800) 39 25 7 26   5 7 (6–9) 4
BEV+   425 (263–600) 44 28 10 18   3 8 (7–10) 3
Rong BEV-    29   1 4 7 1 10 (±50)  
BEV+    26   6 1 3 0 9 (±35)  
Tamandl BEV-    34 7      9 (5–47) 0
BEV+    44 11      8 (4–77) 0
Van der Pool BEV-    32 6    4   7 (3–23) 0
BEV+    25 8    2   6 (3–54) 0
Wicherts BEV- 341 (±110)   36 5 14 2 3 1 11.3 (±7.1) 0
BEV+ 414 (±146)   43 16 8 2 6 2 13.6 (±14.4) 0
Zorzi BEV-    54 39   31     8
BEV+    42 16   26     5
  1. Values are presented as percentages. Continuous data are presented as median (range) or mean (standard deviation) based on the kind of data presented in the original publication. n.r., not reported
\